期刊文献+

宫颈液基细胞学33417例年龄分组统计结果分析 被引量:1

Statistics analysis of women′s cervical liquid-based cytology test
下载PDF
导出
摘要 目的探讨妇科液基细胞学结果与年龄分组的相关关系。方法将2006年11月至2012年2月33 417例在北京市石景山医院妇科门诊做妇科液基细胞学检查患者按年龄分组,统计宫颈上皮异常发病率在各年龄组分布的特点。结果育龄妇女的发病率为8.52%,而非育龄妇女的发病率为6.37%;育龄妇女各年龄组不典型性鳞状细胞(ASC)和不典型腺细胞(AGC)发病率差异无统计学意义(P>0.05),40~49岁组开始轻度下降,但低度鳞状上皮内病变(LSIL)和高度鳞状上皮内病变(HSIL)反而开始升高,癌变发生率最高;非育龄妇女50~59岁年龄组的阳性率为5.87%,有所下降,但仍有各种病变发生;60~69岁和70~79岁组ASC仍然出现,但却没有更严重的病变,为安全期年龄组。结论超薄液基细胞学检查对20~50岁年龄组都有价值,但对60岁以上年龄组价值不大。 Objective To study the correlation of cervical Thinprep cytologic test(TCT) results and the age distribution. Methods The 33 417 cases of cervical Thinprep cytologic test in department of gynecology from november 2006 to february 2012 were grouped by age in this study and diagnosed by TBS project. The correlation of cytological positive cases and their age of onset were analysed. Results (1) The incidence of reproductive women was 8.52% and that of non-reproductive women was 6.37%. The incidence of ASC and AGC was similar in each age stage for reproductive women, although that in 40-49 years old women was descended slightly. However, in this group, the incidence of LSIL and HSIL began to step up, and that of carcinoma was the highest. The incidence rate of positive cases(5.87 % ) in 50-59 years old women was descended, but various kinds of pathological changes were re- main founded. ASC in 60 and 70 age stages was still founded, but more serious pathological change wasnlt founded. Those age stages were safe. Conclusion The TCT technique can have satisfactory applicability for screening cervical pathological changes in 20-50 age stage, but has't in 60 age stage.
出处 《检验医学与临床》 CAS 2012年第23期2947-2948,共2页 Laboratory Medicine and Clinic
关键词 液基细胞学 宫颈病变 年龄分组 thinprep cytologic test cervical lesions age distribution
  • 相关文献

参考文献7

  • 1郝敏,王静芳.宫颈癌流行病学研究与调查[J].国外医学(妇幼保健分册),2005,16(6):404-406. 被引量:91
  • 2郎景和.子宫颈上皮内瘤变的诊断与治疗[J].中华妇产科杂志,2001,36(5):261-263. 被引量:1250
  • 3乐杰.妇产科学[M].6版.北京:人民卫生出版社,2005:145.
  • 4郎景和.子宫颈癌预防的现代策略[J].中国医学科学院学报,2007,29(5):575-578. 被引量:224
  • 5回允中译.Juan Rosai外科病理学[M].9版.北京:北京大学医学出版社,2006:1532.
  • 6Boech FX, Lorincz A, Munoz N. The causal relation between human papillomavirus and cervical cancer[J]. J Clin Pathol, 2002,55(4): 244-265.
  • 7Sellors JW, Mahony LB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada[J]. CMAJ, 2000,163 (5) : 503-508.

二级参考文献19

  • 1Parkin D M,Bray F,Ferlay J,et al.Estimating the world cancer burden:Globocan 2000[J].Int J Cancer,2001,94:153-156.
  • 2Franco,Eduardo L,Duarte F,et al.Cervical cancer:epidemiology,prevention and the role of human papillomavirus infection[ J ].Canadian Medical Association Journal,2001,164(7):1017-1025.
  • 3Torres L A,Rojo H G,Torres R A,et al.Cervical cancer:Current view of its epidemiology and risk factors[ J ].Gynecol Obstet Mex,2004,72:466-474.
  • 4Boyle P,Vecchia C,Walker A,et al.FIGO annual report on the results of treatment in gynecological Cancer[ J ].Journal of epidemiology and biostatictcs,2001,12:7-43.
  • 5Liu J,Rose B,Huang X,et al.Comparative analysis of characteristics of women with cervical cancer in high-versus low-incidence regions[ J].Gynecol Oncol,2004,94(3):803-810.
  • 6Nicolas F S,Andrea T,Eliane D F,et al.Viral load as a predictor of the risk of cervical intraepithelial neoplasia[ J].Int J Cancer,2003,103:519-524.
  • 7Silva D M,Eiben C L,Fausch S C,et al.Cervical cancer vaccines:emerging concepts and developments[ J ].Cell Physiol,2001,186(2):169-182.
  • 8Heley S.Human Papillomavirus:beware the infection you can not see[ J ].Aust Fam Physicion,2003,32 (5):311-315.
  • 9Burd E M.Human Papillomavirus and cervical cancer[ J ].Clin Microbiol Rev,2003,16(1):1-17.
  • 10Andersson S,Safari H,Mints M,et al.Type distribution,viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN)[ J ].Br J Cancer,2005,92(12):2195-2200.

共引文献2211

同被引文献15

  • 1Peirson L, Fitzpatrick-lewis D, Ciliska D, et al. Screening for cervical cancer: a systematic review and meta-analysis [ J]. Syst Rev ,2013 ;2:35.
  • 2Katki HA, Sehiffman M, Castle PE, et al. Benchmarking ein3 + risk as the basis for incorporating hpv and pap eotesting into cervical screening and management guidelines[ J ]. J Low Genit Tract Dis, 2013 ; 17 ( 501 ) : 28-35.
  • 3Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional eervieal cytology:a systematic review and meta - analysis [ J ]. Obstet Gynecol, 2008 ; 111 (1) :167-177.
  • 4Cuzick J, Clavel C, Petry KU, et al. Overview of the european and north american studies on hpv testing in primary cervical cancer screening[ J ]. Int J Cancer,2006; 119(5 ) : 1095-1101.
  • 5Arbyn M, Ronco G, Meijer CJ, et al. Trials comparing cytology with human papillomavirus screening[ J]. Lancet Oncol, 2009 ; 10 ( 10 ) : 935-936.
  • 6K. Ulrich petty, Dietmar sehmidt, Sarah scherbring, et al. l'riaging pap cytology negative, Hpv positive cervical cancer screening results with pl6/Ki- 67dual- stained cytology [ J ]. Gynecologic Oncology, 2011 ; 121 ( 3 ) : 505 -509.
  • 7喻文忠.三阶梯诊断技术在宫颈病变中的临床诊断分析[J].健康之路(医药研究),2015;12(3):12-15.
  • 8赵昀,李静然,赵超,崔淑慧,屠铮,魏丽惠.TruScreen检查在子宫颈癌筛查中的应用研究[J].中国妇产科临床杂志,2009,10(3):225-226. 被引量:13
  • 9和秀魁,罗喜平,毛玲芝,陈桂英,黎云,张江宇.光电探测系统与细胞学检测在宫颈癌筛查中的对照研究[J].南方医科大学学报,2010,30(10):2304-2306. 被引量:12
  • 10朱秀彬.8281例妇女宫颈刮片细胞学情况分析[J].中国初级卫生保健,2011,25(6):61-62. 被引量:6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部